NCT02065024

Brief Summary

Regular consumption of a beverage containing β-cryptoxanthin (b-Cx) and plant sterols (Ps) has been shown to exert a synergic effect in reducing cardiovascular risk and bone remodeling markers (formation and resorption). The present project aims to assess the influence of technological treatment and genetic variability on the bioavailability and the health effects of the added components (Ps, b-Cx), in particular to their potential role in prevalent disorders.In vitro and in vivo studies will be carried out to this effect. In vitro and in vivo studies (human intervention study) will be performed and cardiovascular, bone turnover and inflammation markers will be evaluated. Additionally, an in vitro colonic fermentation model and cell cultures will be used to explore anticarcinogenic effects and potential cytotoxicity.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
40

participants targeted

Target at P50-P75 for phase_1

Timeline
Completed

Started Mar 2014

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

February 7, 2014

Completed
10 days until next milestone

First Posted

Study publicly available on registry

February 17, 2014

Completed
12 days until next milestone

Study Start

First participant enrolled

March 1, 2014

Completed
1.4 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

August 1, 2015

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

August 1, 2015

Completed
Last Updated

April 10, 2018

Status Verified

April 1, 2018

Enrollment Period

1.4 years

First QC Date

February 7, 2014

Last Update Submit

April 6, 2018

Conditions

Keywords

b-cryptoxanthinplant sterolsserum Cholesterolbone turnover markers

Outcome Measures

Primary Outcomes (2)

  • serum response of B-cryptoxanthin

    6 weeks of intervention

  • Serum response of phytosterols

    6 weeks

Secondary Outcomes (7)

  • Serum lipid profile

    6 weks of intervention

  • bone resorption markers

    6 weeks

  • interleukins

    6 weeks

  • Serum C-reactive protein

    6 weeks

  • Bone formation markers

    6 weeks

  • +2 more secondary outcomes

Other Outcomes (1)

  • Intestinal transporters polymorphisms,

    Baseline

Study Arms (2)

b-cryptoxanthin plus phytosterols

ACTIVE COMPARATOR

Fruit and milk based beverage enriched with b-cryptoxanthin and phytosterols

Dietary Supplement: b-cryptoxanthin plus phytosterols

control

PLACEBO COMPARATOR

Fruit and milk based beverage not enriched

Dietary Supplement: b-cryptoxanthin plus phytosterols

Interventions

b-cryptoxanthin plus phytosterolscontrol

Eligibility Criteria

Age45 Years - 65 Years
Sexfemale
Healthy VolunteersYes
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Post-menopausal women; mild hypercholesterolemia

You may not qualify if:

  • Use of cholesterol lowering drugs, hormonal therapy, vitamin and herbs supplements use

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Hospital Universitario Puerta de Hierro-Majadahonda

Majadahonda (Madrid), Madrid, 28222, Spain

Location

Related Publications (1)

  • Cuevas-Tena M, Bermudez JD, Silvestre RLA, Alegria A, Lagarda MJ. Impact of colonic fermentation on sterols after the intake of a plant sterol-enriched beverage: A randomized, double-blind crossover trial. Clin Nutr. 2019 Aug;38(4):1549-1560. doi: 10.1016/j.clnu.2018.08.012. Epub 2018 Sep 7.

MeSH Terms

Conditions

HypercholesterolemiaOsteoporosis

Interventions

Phytosterols

Condition Hierarchy (Ancestors)

HyperlipidemiasDyslipidemiasLipid Metabolism DisordersMetabolic DiseasesNutritional and Metabolic DiseasesBone Diseases, MetabolicBone DiseasesMusculoskeletal Diseases

Intervention Hierarchy (Ancestors)

SterolsCholestanesSteroidsFused-Ring CompoundsPolycyclic CompoundsMembrane LipidsLipidsPhytochemicalsBiological Factors

Study Design

Study Type
interventional
Phase
phase 1
Allocation
RANDOMIZED
Masking
DOUBLE
Who Masked
PARTICIPANT, OUTCOMES ASSESSOR
Purpose
BASIC SCIENCE
Intervention Model
CROSSOVER
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
dr Fernando Granado Lorencio

Study Record Dates

First Submitted

February 7, 2014

First Posted

February 17, 2014

Study Start

March 1, 2014

Primary Completion

August 1, 2015

Study Completion

August 1, 2015

Last Updated

April 10, 2018

Record last verified: 2018-04

Locations